Immunogenicity of intensively decellularized equine carotid arteries is conferred by the extracellular matrix protein collagen type VI.
Authors: Boeer Ulrike, Buettner Falk F R, Klingenberg Melanie, Antonopoulos Georgios C, Meyer Heiko, Haverich Axel, Wilhelmi Mathias
Journal: PloS one
Summary
# Editorial Summary Decellularised scaffolds show considerable promise as grafts and implants in equine regenerative medicine, yet residual immunogenicity remains a significant clinical limitation. Researchers subjected equine carotid arteries to an intensified decellularisation protocol using SDS and sodium desoxycholate over 72 hours with increased volumes, then compared the immunogenic response to conventionally decellularised tissue using laboratory mouse immunisation models and mass spectrometry analysis. Whilst the intensive protocol successfully removed 97.8% of MHC I complexes, 98.4% of alpha-gal epitopes, and achieved near-complete depletion of smooth muscle cells (100%), antibody formation still occurred—though at substantially lower levels than with standard decellularisation—because collagen type VI within the extracellular matrix remained immunogenic. The identification of collagen VI alpha chains as the primary culprit means that future efforts to improve scaffold biocompatibility should focus specifically on removing or masking this protein rather than pursuing further aggressive decellularisation that risks compromising structural integrity. For practitioners considering decellularised tissue products, this finding highlights the importance of understanding which decellularisation protocols have been used, as intensified protocols appear to offer measurably better immunological outcomes than standard approaches without sacrificing matrix architecture.
Read the full abstract on PubMed
Practical Takeaways
- •If using decellularized equine arterial scaffolds clinically, recognize that complete cellular removal does not guarantee non-immunogenic material—ECM proteins like collagen VI can still trigger immune responses
- •Longer, more intensive decellularization protocols show promise in reducing immunogenicity; continued refinement of processing parameters may improve clinical outcomes
- •Current decellularized equine carotid artery products require careful immunological assessment before use, particularly in applications where graft rejection is a concern
Key Findings
- •Intensively decellularized equine carotid arteries (dEAC) achieved 97.8% removal of MHC I complexes and 98.4% removal of alphaGal epitopes with minimal structural changes
- •Residual immunogenicity in completely decellularized tissue is conferred by extracellular matrix collagen VI (140 kDa protein) rather than cellular components
- •Intensified decellularization protocol (72 h SDS/sodium desoxycholate) produced lower antibody formation compared to standard protocol (40 h), indicating potential for further optimization